RT3
25% off when buying 10+ items (any product)
RT3 | Peptide Complex
Metabolic
RT3 (LY3437943) is a next-generation triple receptor agonist that simultaneously targets GIP, GLP-1, and glucagon receptors. Developed as a potential advancement beyond dual-agonist compounds, RT3 has generated significant clinical research interest for its remarkable effects on body weight reduction, glycemic control, and metabolic function.
Triple Receptor Agonism — RT3 simultaneous activation of GIP, GLP-1, and glucagon receptors produces a synergistic metabolic effect beyond what single or dual agonists achieve in research models.
Weight Reduction Research — Phase 2 clinical trials have demonstrated substantial reductions in body weight, positioning RT3 among the most potent compounds studied for metabolic and obesity research.
Glycemic Control — Like other GLP-1 class compounds, RT3 has shown significant improvements in insulin sensitivity and blood glucose regulation in research subjects.
Cardiovascular Markers — Early research indicates favorable effects on lipid profiles, blood pressure, and other cardiovascular risk markers in metabolic disease models.
Energy Expenditure — The glucagon receptor component is believed to increase basal metabolic rate and hepatic fat oxidation, contributing to its pronounced effects on body composition research.
